Business
Viveve(R) Announces Closing of $15.5 Million Underwritten Public Offering
Viveve(R) Announces Closing of $15.5 Million Underwritten Public Offering.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve(R) Announces Closing of $15.5 Million Underwritten Public Offering\n\nViveve(R) Announces Closing of $15.5 Million Underwritten Public Offering\n\nSUNNYVALE, CA--(Marketwired - June 17, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the closing of its previously announced underwritten public offering of approximately 3,105,000 shares of its common stock, including the exercise of the underwriters' overallotment option, at a public offering price of $5.00 per share. Gross offering proceeds to the company are approximately $15.5 million, while net proceeds, after deducting underwriting discounts, commissions and estimated offering expenses, are estimated to be approximately $14 million.Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., and Craig-Hallum Capital Group LLC are the joint book-running managers of the offering and Maxim Group LLC is acting as co-manager.This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The securities described above are being offered by Viveve pursuant to a registration statement previously filed and declared effective by the U.S. Securities and Exchange Commission. A prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Ladenburg Thalmann & Co., Inc., 570 Lexington Avenue, 11th Fl., New York, NY 10022, (212) 409-2000 or by accessing the SEC's website, www.sec.gov.About ViveveViveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician survey...